CVE-2026-5286
CWE-416Published: April 1, 2026· Updated: Apr 1, 2026
Official Description
Use after free in Dawn in Google Chrome prior to 146.0.7680.178 allowed a remote attacker to execute arbitrary code via a crafted HTML page. (Chromium security severity: High)
Technical Analysis
CVE-2026-5286 can be exploited remotely over the network without requiring physical or adjacent access, significantly expanding the attack surface for threat actors.
Exploitation does not require any privileges, though user interaction (Required) is needed, which slightly reduces the risk of mass automated attacks.
A successful exploit results in complete confidentiality breach (data exposure), full integrity compromise (data manipulation), availability disruption (denial of service), with a CVSS base score of 8.8.
From a weakness classification perspective (CWE-416): Use-after-free vulnerabilities involve accessing memory after it has been freed, often enabling arbitrary code execution.
CVSS v3.1 Vector Breakdown
Affected Vendors & Products
Exploit & PoC Resources
Official Patches & Advisories
News & Research Mentioning CVE-2026-5286
View CSAF Summary Successful exploitation of these vulnerabilities could allow an attacker to write files, access unauthorized information, exhaust memory, or crash affected DCMTK client or server processes. The following versions of OFFIS DCMTK Toolkit are affected: DCMTK <=3.7.0 (CVE-2026-50003, CVE-2026-50254, CVE-2026-35505, CVE-2026-52868, CVE-2026-44628) CVSS Vendor Equipment Vulnerabilities v3 9.8 OFFIS OFFIS DCMTK Toolkit Improper Limitation of a Pathname to a Restricted Directory ('Path Traversal'), Missing Release of Memory after Effective Lifetime, Access of Resource Using Incompatible Type ('Type Confusion') Background Critical Infrastructure Sectors: Healthcare and Public Health Countries/Areas Deployed: Worldwide Company Headquarters Lo [xlite_meta score:79 src:CISA Alerts xlite_fp:b3b1b9b0fd71bd524412d70c33aa2f0a83634e4d08a0bd993fad563f7612dede]
View CSAF Summary Successful exploitation of these vulnerabilities could allow an attacker to obtain sensitive health-related information and prevent legitimate users from establishing a connection with the device. The following versions of Apollo Pharmacy Blood Glucose Monitoring System APG-01 BT are affected: Blood Glucose Monitoring System (Model No. APG-01 BT) 0x0110_v1.1.0 (CVE-2026-50034, CVE-2026-52866) CVSS Vendor Equipment Vulnerabilities v3 6.5 Apollo Pharmacy Apollo Pharmacy Blood Glucose Monitoring System APG-01 BT Cleartext Transmission of Sensitive Information, Missing Authorization Background Critical Infrastructure Sectors: Healthcare and Public Health Countries/Areas Deployed: India Company Headquarters Location: India Vulnerabilitie [xlite_meta score:73 src:CISA Alerts xlite_fp:a8c7a750538e2275ea8b101c510eb9fe37a577d1b98dcb09de66caf6a763a018]
All References (2)
Quick Facts
Related CVEs (CWE-416)
Recommended Actions
- →Apply vendor patches immediately
- →Monitor CVE-2026-5286 in threat intel feeds
- →Review IDS/IPS signatures for exploitation attempts